Regeneron Pharmaceuticals Inc (REGN) — Cash Flow-to-Debt Ratio
Regeneron Pharmaceuticals Inc (REGN) has a Cash Flow-to-Debt Ratio of 0.11x as of March 2026, meaning its operating cash flow of $1.08 Billion could theoretically repay 0% of its total liabilities ($9.45 Billion) in one year. Explore how much of Regeneron Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Regeneron Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1991–2025)
Historical debt coverage capacity for Regeneron Pharmaceuticals Inc across 35 annual periods. Also explore REGN total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Regeneron Pharmaceuticals Inc (1991–2025)
Year-by-year debt coverage analysis for Regeneron Pharmaceuticals Inc. For market capitalisation and broader financial context, see Regeneron Pharmaceuticals Inc (REGN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.54x | $4.98 Billion | $9.30 Billion | ▲ +1.8% |
| 2024 | 0.53x | $4.42 Billion | $8.41 Billion | ▼ -18.6% |
| 2023 | 0.65x | $4.59 Billion | $7.11 Billion | ▼ -15.6% |
| 2022 | 0.77x | $5.01 Billion | $6.55 Billion | ▼ -27.9% |
| 2021 | 1.06x | $7.08 Billion | $6.67 Billion | ▲ +149.1% |
| 2020 | 0.43x | $2.62 Billion | $6.14 Billion | ▼ -34.8% |
| 2019 | 0.65x | $2.43 Billion | $3.72 Billion | ▼ -11.3% |
| 2018 | 0.74x | $2.20 Billion | $2.98 Billion | ▲ +47.8% |
| 2017 | 0.50x | $1.31 Billion | $2.62 Billion | ▼ -15.3% |
| 2016 | 0.59x | $1.49 Billion | $2.52 Billion | ▼ -13.6% |
| 2015 | 0.68x | $1.33 Billion | $1.95 Billion | ▲ +20.3% |
| 2014 | 0.57x | $752.43 Million | $1.33 Billion | ▼ -3.9% |
| 2013 | 0.59x | $588.60 Million | $998.94 Million | ▲ +759.5% |
| 2012 | -0.09x | $-74.61 Million | $835.11 Million | ▲ +47.2% |
| 2011 | -0.17x | $-141.68 Million | $837.85 Million | ▼ -198.6% |
| 2010 | 0.17x | $96.34 Million | $561.62 Million | ▲ +181.8% |
| 2009 | -0.21x | $-72.23 Million | $344.44 Million | ▲ +40.9% |
| 2008 | -0.35x | $-89.09 Million | $251.19 Million | ▼ -716.7% |
| 2007 | 0.06x | $27.37 Million | $475.99 Million | ▼ -8.2% |
| 2006 | 0.06x | $23.07 Million | $368.47 Million | ▲ +164.0% |
| 2005 | -0.10x | $-30.30 Million | $309.50 Million | ▼ -68.2% |
| 2004 | -0.06x | $-16.91 Million | $290.56 Million | ▼ -224.4% |
| 2003 | -0.02x | $-6.13 Million | $341.91 Million | ▲ +96.0% |
| 2002 | -0.45x | $-110.52 Million | $245.59 Million | ▼ -79.8% |
| 2001 | -0.25x | $-57.32 Million | $229.04 Million | ▲ +76.6% |
| 2000 | -1.07x | $-27.91 Million | $26.14 Million | ▼ -112.7% |
| 1999 | -0.50x | $-13.80 Million | $27.50 Million | ▼ -26.4% |
| 1998 | -0.40x | $-10.20 Million | $25.70 Million | ▼ -91.9% |
| 1997 | -0.21x | $-6.10 Million | $29.50 Million | ▲ +68.7% |
| 1996 | -0.66x | $-20.30 Million | $30.70 Million | ▲ +5.9% |
| 1995 | -0.70x | $-18.20 Million | $25.90 Million | ▲ +7.1% |
| 1994 | -0.76x | $-20.50 Million | $27.10 Million | ▲ +51.7% |
| 1993 | -1.57x | $-30.10 Million | $19.20 Million | ▲ +2.5% |
| 1992 | -1.61x | $-17.20 Million | $10.70 Million | ▼ -84.4% |
| 1991 | -0.87x | $-6.80 Million | $7.80 Million | — |